Patents by Inventor Davide Corti

Davide Corti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220127336
    Abstract: The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 28, 2022
    Inventor: Davide CORTI
  • Publication number: 20220073595
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 10, 2022
    Inventors: Christine TKACZYK, Bret SELLMAN, Martin BORROK, III, Davide CORTI, Andrea MINOLA
  • Publication number: 20220064267
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that potently neutralize lyssavirus infection and the use of such antibodies. In particular, the invention provides methods of treatment of lyssavirus infection, such as rabies.
    Type: Application
    Filed: October 18, 2019
    Publication date: March 3, 2022
    Inventors: Davide CORTI, Hervé BOURHY, Florian SONTHONAX, Gabriel LEPOUSEZ, Guilherme DIAS DE MELO
  • Patent number: 11261245
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 1, 2022
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Davide Corti, Antonio Lanzavecchia, Luca Piccoli
  • Publication number: 20220056110
    Abstract: The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies include an inhibitor of HBV gene expression or an agent that reduces HBV antigenic load, and an anti-HBV antibody.
    Type: Application
    Filed: December 19, 2019
    Publication date: February 24, 2022
    Inventors: Anna Bakardjiev, Phillip S. Pang, Davide Corti
  • Publication number: 20220056113
    Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 24, 2022
    Inventors: Qun WANG, Charles K. STOVER, Meghan PENNINI, Chew-shun CHANG, Xiaodong XIAO, Jamese HILLIARD, Gilad KAPLAN, Davide CORTI, Elisabetta CAMERONI, Martina BELTRAMELLO
  • Publication number: 20220033480
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 3, 2022
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Publication number: 20220024987
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Publication number: 20220025020
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
  • Publication number: 20210371504
    Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 2, 2021
    Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
  • Patent number: 11186627
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 30, 2021
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Publication number: 20210363229
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 25, 2021
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Davide CORTI, Andrea MINOLA
  • Publication number: 20210363227
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.
    Type: Application
    Filed: June 1, 2021
    Publication date: November 25, 2021
    Inventor: Davide CORTI
  • Publication number: 20210355198
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.
    Type: Application
    Filed: June 1, 2021
    Publication date: November 18, 2021
    Inventor: Davide CORTI
  • Patent number: 11174304
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: November 16, 2021
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • Patent number: 11168128
    Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: November 9, 2021
    Assignee: VIR BIOTECHNOLOGY, INC.
    Inventors: Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
  • Patent number: 11155606
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 26, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
  • Publication number: 20210284718
    Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that are specific for Campylobacter and, in certain embodiments, are capable of neutralizing a Campylobacter infection in a subject. In certain embodiments, the antibody or antigen binding fragment comprises an IgA antibody, such as, for example, a secretory IgA antibody. Also provided are pharmaceutical compositions comprising a disclosed antibody or antigen-binding fragment. Methods of using the antibodies, antigen-binding fragments, and compositions to treat or prevent a Campylobacter infection in a subject are also provided. In certain embodiments, recombinant secretory IgA antibodies of the instant disclosure are administered orally to a subject having or at risk of developing a Campylobacter infection.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 16, 2021
    Inventors: Matteo PIZZUTO, Fabio BENIGNI, Davide CORTI, Fabio GRASSI, Lisa PERRUZZA
  • Publication number: 20210283240
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 16, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 11117956
    Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 14, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Qun Wang, Charles Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello